Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) posted its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($200.00) by $199.94, reports.
Hepion Pharmaceuticals Price Performance
HEPA stock remained flat at $0.12 during midday trading on Wednesday. The company had a trading volume of 32,939 shares, compared to its average volume of 27,637. The firm has a 50 day moving average of $0.11 and a two-hundred day moving average of $0.07. Hepion Pharmaceuticals has a twelve month low of $0.03 and a twelve month high of $0.22. The company has a market cap of $1.32 million, a PE ratio of -0.03 and a beta of 1.52.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. Its research centered on rencofilstat, an investigational oral cyclophilin inhibitor studied for conditions including nonalcoholic steatohepatitis (NASH) and liver fibrosis. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name in 2019. Its work included clinical development of rencofilstat; the candidate was investigational and had not been approved as a treatment.
Read More
- Five stocks we like better than Hepion Pharmaceuticals
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
